{"groups":[{"description":"Participants received apalutamide matched placebo tablets orally on a continuous once daily dosing regimen along with androgen deprivation therapy (ADT) until disease progression, withdrawal of consent or unacceptable toxicity or death.","id":"FG000","title":"Placebo"},{"description":"Participants received apalutamide orally at a starting dose of 240 milligram (mg) (8 x 30 mg capsules then 4 x 60 mg tablets) in a continuous treatment cycles (each treatment cycle is of 28 days) once daily dosing regimen along with androgen deprivation therapy (ADT) until disease progression, withdrawal of consent or unacceptable toxicity or death.","id":"FG001","title":"Apalutamide"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"38"},{"groupId":"FG001","numSubjects":"59"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"37"},{"groupId":"FG001","numSubjects":"50"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"7"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"316"},{"groupId":"FG001","numSubjects":"687"}],"type":"Ongoing"},{"reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"3"}],"type":"Other"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"401"},{"groupId":"FG001","numSubjects":"806"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"398"},{"groupId":"FG001","numSubjects":"803"}],"type":"Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"401"},{"groupId":"FG001","numSubjects":"806"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}